A prealbumin like protein (AFp) associated with amyloid was first described in 1978 by Costa et al in Portuguese familial amyloidotic polyneuropathy (FAP) .' Shortly afterwards protein AScl, which had previously been isolated from senile cardiac amyloid,2 was also reported to be related to prealbumin.3 Senile cardiac amyloid has subsequently been designated senile systemic amyloid (SSA). 4 5 Since these initial findings, other forms of FAP (Japanese, Jewish, Swedish-American, German-English, Swedish) and familial amyloidotic cardiomyopathy (Danish) have been shown to contain proteins related to prealbumin.6-" Despite the apparent similarity in the biochemical nature of SSA and FAP the clinical manifestations of these two forms of amyloidosis are strikingly different. On the one hand, SSA occurs in late life and is generally associated with minor clinical manifestations; by contrast, FAP is generally a disease of early and middle age and is always fatal.
Prealbumin
Human prealbumin is a product ofchromosome 18.12 It is a tetrameric protein of 55 kD molecular weight, composed of four identical non-covalently bound monomers of 127 amino acid residues arranged with tetrahedral symmetry. 1'3A narrow cylindrical channel runs through the centre of the protein molecule and contains two binding sites for thyroxin.'4 Independent binding sites for retinol binding protein, the specific plasma carrier of vitamin A, are probably Accepted for publication 11 August 1986 located on the outside of each subunit.'5 Each dimer contains two f sheets, composed of eight strands,'6 a structure which may account for its unusual stability and resistance to dissociation. The f structure makes human prealbumin an ideal candidate for the deposition of twisted ,B pleated sheet fibrils into amyloid deposits. This conclusion is based on x-ray and infrared analysis of systemic and localised amyloid fibrils, which show that they have a f pleated sheet configuration. 1 7 Senile systemic amyloid (SSA) CLINICAL 
FEATURES
Senile systemic amyloid is a disease related to age, which has a predisposition for the heart. The incidence and distribution of SSA was determined in a prospective immunohistochemical study of atrium, ventricle, aorta, lung, renal cortex and rectum removed at necropsy from 85 consecutive elderly patients (80 years or older). Twenty one patients (25%) had SSA (AScl) type amyloid. Of this group, 17 had cardiac disease and 19 had small extracardiac deposits.4 Although the mean heart weight, percentage with heart failure, and incidence of myocardiac infarction were higher for the group of patients with cardiac amyloid, none of these differences was significant in this small group of patients.
The widespread nature of ASc, type amyloid was subsequently confirmed in 13 patients who died from extensive ASc, type amyloid infiltration of the heart (mean heart weight 598 g; range 370-950 g). The (table 2) . 18 SSA deposits in tissue sections react strongly by immunofluorescence with antihuman prealbumin and Smaller proteins (i) Some of these proteins contain cysteine; (ii) some react strongly with anti-ASc1 and weakly with antihuman prealbumin. Thus these proteins seem to be fragmentation products of the prealbumin like protein or the 13 kD protein, or both.
The prealbumin like protein of SSA has recently Prealbumin: its association with amyloid 33 Patients with these four types of FAP have the Val-iMet prealbumin variant (as well as normal prealbumin) in the serum or plasma.33 3536 The Val-+Met substitution does not affect the ability ofmonomers to form stable tetremers, nor the binding affinity for retinol-binding protein or thyroxin. 33 The prealbumin variant in the Jewish type, by contrast, has a substitution at position 49 (Thr--Gly)29 or position 33 (Phe-Ile). 37 A nonapeptide containing the substituted methionine at position 30 has been synthesised, and an antibody to this peptide has been used to identify circulating human prealbumin variant by radioimmunoassay.38 This assay seems to have identified Japanese family members at risk before clinical disease of the nervous system occurred. The variant prealbumin molecule has also been identified as a preclinical marker in the serum or plasma of SwedishAmerican and Portuguese family members. Human prealbumin has been isolated from these subjects and has been digested with cyanogen bromide (which cleaves at the methonine residue). The additional peptides derived from the mutant prealbumin have been identified by purification and sequencing39 or by immunoblotting techniques. 40 In addition, DNA isolated from peripheral blood leucocytes of three Japanese patients with FAP has been shown to contain new restriction sites for endonuclease NsiI or BalI in the prealbumin locus.41 These mutations were consistent with the substitution of adenine (A) for guanine (G). The resultant change in the nucleotide sequence from GTG to ATG explains the substitution of methionine for valine at position 30 in prealbumin. Similar findings have been reported in the offspring of patients with Portuguese FAP."
The absence of additional variant nucleotide sequences in these subjects supports the hypothesis that the prealbumin variant associated with SSA entails one or more post-translational events.
Familial cardiac amyloid was first discovered in a Danish family4 and has recently been shown to contain prealbumin.1 The disease has its onset in early to middle age and leads to progressive cardiac failure and death over two to six years. Several other organs (skin, spleen, kidney) and fat have been affected in some patients. 
Conclusions
The amyloid fibril proteins ASc1 and AF, associated with SSA and FAP, respectively, contain prealbumin variants. These variants seem to contain several protein components, one of which may be very similar to normal prealbumin. In most types of human prealbumin related FAP studied to date this protein has at least one amino acid substitution. A smaller component appears to lack cysteine and reacts poorly with antiprealbumin. This is the major component of ASc1 and of AFs in some patients and can be detected with anti-ASc1. The finding of a similar smaller protein in ASci and AFs is consistent with the observation that anti-ASc1 reacts both with ASc1 and AFs in double diffusion but fails to react with native prealbumin. As sera or plasma from four different types of FAP have shown a prealbumin variant with an amino acid substitution at position 30, it is speculated that this abnormality leads to important conformational changes of the prealbumin molecule, which change its precipitability and contribute to the amyloidogenic potential of these proteins.
Unlike the prealbumin variants found in amyloid fibrils and blood of FAP patients and family members, no direct evidence of amino acid substitution has yet been shown for protein AScl. The deletion of cysteine from the N-terminus in the 13kD protein of ASc1 may be caused by post-translational cleavage of the prealbumin monomer. Alternatively, it is possible that the cysteine residue is modified and not detectable 230 Cornwell, Sletten, Olofsson, Johansson, Westermark by the`4C-iodoacetamide reaction, which was used to identify this amino acid. To date no structural studies of putative circulating prealbumin variants have yet been performed in patients with SSA.
The clinical diversity of the prealbumin related amyloidoses represents an important challenge to our better understanding of the associated prealbumin variants and their role in the mechanisms and sites of amyloid deposition.
